Published on
Last month, Professor Erika Lietzan participated in a webinar hosted by the Eira Initiative, a new research initiative in biopharmaceutical innovation and entrepreneurship policy. The initiative, which is a project of the BRG Institute (founded and led by Prof. David Teece of the UC Berkeley Haas School of Business), seeks to cultivate an international community of researchers committed to evidence-based approaches to assessing and developing public policies to facilitate innovation and entrepreneurship in the U.S. and global biopharmaceutical ecosystem.
The webinar — which featured a small panel of experts — presented the vision for this new initiative and discussed a new report laying out, from an economic perspective and grounded in empirical research, how intellectual property rights play critical functions in the biopharmaceutical system that support innovation, entrepreneurship, and competition.
Professor Lietzan spoke about the role of patent-based and non-patent-based exclusivities for new drugs, a topic on which she has also written numerous articles. The webinar discussion, which also featured the Hon. Paul Michel, former Chief Judge of the U.S. Courts of Appeals of Appeals for the Federal Circuit, and David Kappos, former Under Secretary of Commerce and Director of the U.S. Patent and Trademark Office, can be found here.